Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BULENT OZPOLAT and GEORGE A CALIN.
BULENT OZPOLAT
Connection Strength
2.329
GEORGE A CALIN
  1. Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 2023 Oct 31; 14:908-909.
    View in: PubMed
    Score: 0.232
  2. miRacle of microRNA-Driven Cancer Nanotherapeutics. Cancers (Basel). 2022 Aug 06; 14(15).
    View in: PubMed
    Score: 0.213
  3. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022 03; 182:114113.
    View in: PubMed
    Score: 0.205
  4. Non-coding RNAs regulation of macrophage polarization in cancer. Mol Cancer. 2021 02 01; 20(1):24.
    View in: PubMed
    Score: 0.192
  5. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Mol Ther Nucleic Acids. 2021 Mar 05; 23:930-943.
    View in: PubMed
    Score: 0.192
  6. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Res Treat. 2018 Oct; 171(3):593-605.
    View in: PubMed
    Score: 0.161
  7. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clin Cancer Res. 2018 09 01; 24(17):4225-4241.
    View in: PubMed
    Score: 0.159
  8. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 2017 Feb 14; 8(7):11641-11658.
    View in: PubMed
    Score: 0.146
  9. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Mol Cancer. 2024 Aug 02; 23(1):156.
    View in: PubMed
    Score: 0.061
  10. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. medRxiv. 2024 Mar 15.
    View in: PubMed
    Score: 0.060
  11. Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2023 Nov 08; 9(1):111.
    View in: PubMed
    Score: 0.058
  12. Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer. Annu Int Conf IEEE Eng Med Biol Soc. 2023 07; 2023:1-4.
    View in: PubMed
    Score: 0.057
  13. Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell Death Dis. 2022 05 21; 13(5):485.
    View in: PubMed
    Score: 0.053
  14. Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharm Res. 2022 Mar; 39(3):511-528.
    View in: PubMed
    Score: 0.052
  15. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2022 Jan; 89:110147.
    View in: PubMed
    Score: 0.051
  16. Corrections to "A multiscale Agent-Based Model of Ductal Carcinoma in Situ". IEEE Trans Biomed Eng. 2021 02; 68(2):736.
    View in: PubMed
    Score: 0.048
  17. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. EBioMedicine. 2020 Feb; 52:102630.
    View in: PubMed
    Score: 0.045
  18. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 04; 68:109539.
    View in: PubMed
    Score: 0.045
  19. A Multiscale Agent-Based Model of Ductal Carcinoma In Situ. IEEE Trans Biomed Eng. 2020 05; 67(5):1450-1461.
    View in: PubMed
    Score: 0.044
  20. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Mol Ther Nucleic Acids. 2019 Mar 01; 14:301-317.
    View in: PubMed
    Score: 0.041
  21. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018 Dec; 38:100-112.
    View in: PubMed
    Score: 0.041
  22. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2017; 3:17029.
    View in: PubMed
    Score: 0.038
  23. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 2017 Mar 21; 8(12):20145-20164.
    View in: PubMed
    Score: 0.037
  24. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 2016 12 15; 76(24):7194-7207.
    View in: PubMed
    Score: 0.036
  25. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351.
    View in: PubMed
    Score: 0.033
  26. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 01; 21(9):2127-37.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.